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a b s t r a c t
Defects in mitochondrial function are increasingly recognised as central to the pathogenesis of many
diseases, both inherited and acquired. Many of these mitochondrial defects arise from abnormalities in
mitochondrial DNA and can result in multisystem disease, with gastrointestinal involvement common.
Moreover, mitochondrial disease may present with a range of non-speciﬁc symptoms, and thus can be
easily misdiagnosed, or even considered to be non-organic.
We describe the clinical, histopathological and genetic ﬁndings of six patients from three families with
gastrointestinal manifestations of mitochondrial disease. In two of the patients, anorexia nervosa was
considered as an initial diagnosis. These cases illustrate the challenges of both diagnosing and managing
mitochondrial disease and highlight two important but poorly understood aspects, the clinical and the
genetic.
The pathophysiology of gastrointestinal involvement inmitochondrial disease is discussed and emerg-
ing treatments are described. Finally, we provide a checklist of investigations for the gastroenterologist
when mitochondrial disease is suspected.
Gast© 2013 Editrice
. Introduction
Defects in mitochondrial function are increasingly recognised
s central to the pathogenesis of many diseases, both inherited
nd acquired [1]. Mitochondria are dynamic organelles present in
very nucleated cell and play an essential role in cellular energy
roduction. Consequently mitochondrial defects can result in dys-
unction of almost any organ, particularly those with high energy
emand.
Many of these mitochondrial defects result from abnormali-
ies in mitochondrial DNA (mtDNA). While mtDNA disease may
esult from sporadic mutations, when transmission does occur it is
lassically through the maternal line, as either point mutations or
omplex mtDNA rearrangements [2–4]. However, as mtDNA relies
pon the cell nucleus for replication and maintenance, nuclear
ene defects can result in secondary mtDNA abnormalities. This
s seen in mitochondrial neurogastrointestinal encephalomyopa-
hy (MNGIE), which is inherited as an autosomal recessive disorder
∗ Corresponding author at: Translational Gastroenterology Unit, John Radcliffe
ospital, Oxford OX3 9DU, UK. Tel.: +44 1865 228753; fax: +44 1865 228763.
E-mail address: simon.travis@ndm.ox.ac.uk (S.P. Travis).
590-8658/$36.00 © 2013 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier
ttp://dx.doi.org/10.1016/j.dld.2013.04.008roenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
[5]. In addition, there are many other genes involved in mitochon-
drial biogenesis and dynamics; an example is the OPA1 gene which
plays a key role in mitochondrial dynamics, with mutations lead-
ing to optic atrophy syndromes [6]. Fig. 1 provides an overview
of the common abnormalities in the mitochondrial genome, and
the associated diseases. The diverse group of disorders that result
from mitochondrial disease are described in greater detail in the
following articles [7,8].
Mitochondrial disease is more common than previously
thought, with an estimated prevalence of 1 in 500 [9]. Greater
awareness of mitochondrial disease and improvements in analyt-
ical technique have led to improved detection of simple mtDNA
defects, such as the single deletion commonly seen in Chronic Pro-
gressive External Ophthalmoplegia [10]. However, more complex
mtDNA rearrangements which classically result in multisystem
disease are still greatly under-diagnosed. This is partly because
multisystem mitochondrial disease may present to many medical
specialties without being diagnosed.
The prevalence of medically unexplained symptoms (MUS) in
outpatients is common and ranges between 25% and 75% [11].
Comorbid psychiatric disorders are frequent in such patients, who
present major challenges to conventional medical management,
are commonly frequent attenders and may have misattributed
Ltd. All rights reserved.
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Fig. 1. Diagram of the human mitochondrial genome and sites of mutations leading to important clinical phenotypes. Adapted from “Seminars in medicine of the Beth
Israel Hospital, Boston. Mitochondrial DNA and disease” by Johns [7]. The 16,569np mtDNA map demonstrates the genes for the subunits of NADH dehydrogenase (ND),
cytochrome c oxidase (COX), cytochrome b (cyt b), ribosomal RNA (12S and 16S) and ATPase (A6 and A8). LHON, Leber’s hereditary optic neuropathy; MELAS, syndrome
of mitochondrial encephalomyopathy, lactic acidosis and stroke like episodes; LS, Leigh’s syndrome; NARP, neuropathy, ataxia and retinitis pigmentosa; MILS, maternally
inherited Leigh’s syndrome; MERRF, myoclonic epilepsy with ragged-red ﬁbres.
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rganic disease has been excluded [11]. Gastrointestinal involve-
ent is common in patients with mtDNA disease, affecting up to
5%, yet symptoms are frequently overlooked as they may be non-
peciﬁc such as abdominal pain, chronic constipation or vomiting
12]. Other manifestations include severe gut dysmotility and pro-
oundweight loss,whichmaybeamong theprincipal presentations
fmitochondrial disease, as inMNGIE [13]. Importantly,mitochon-
rial disease can be easily mistaken for anorexia nervosa. Indeed
he misdiagnosis of organic disease as ‘anorexia nervosa’ is well
ecognised in the literature [14–17].
In addition to the often non-speciﬁc presentation of mitochon-
rial disease, the genetics present further challenges to diagnosis.
irstly, even when sought, underlying complex mtDNA rearrange-
ents are often missed by routine analytical techniques or are
ndistinguishable from simple, single deletions, consistent with
ow overall rates of detection [5,18,19]. Accurately deﬁning the
enetics has important implications both for the transmission and
linical presentation of mitochondrial disease. Complex mtDNA
earrangements including duplications are frequently maternally
nherited andmulti-systemic, whereas simple deletions are gener-
lly sporadic and myopathic. Secondly, there is marked variability
n clinical presentation of mtDNA disorders, even within the same
amily andwith apparently similar genotypes. Two unique features
f mitochondrial genetics play an important role in determining
henotypic differences: these are heteroplasmy (the existence of
wo or more mitochondrial genotypes within the same cell, the
roportion of which may vary both between and within indi-
iduals) and the threshold effect (the level of mutant mtDNA
oad necessary for clinical expression), but there is still much to
xplain [1]. A better understanding of complexmtDNAmutations is
ssential to provide further insight; it is likely that incomplete
apping of complex mtDNA rearrangements may account for
ome of the unexplained phenotypic variation seen with mtDNA
isorders.2. Case series
2.1. Family A
Three siblings froma consanguineous family (mother and father
were ﬁrst cousins), who initially presented with medically unex-
plained gastrointestinal and neurological symptoms are described,
in whom the diagnosis of a mitochondrial disease due to MNGIE
was subsequently established. The genetic pedigree is shown in
Fig. 2. A psychiatric disorder (anorexia nervosa) was considered in
two of the family members.Fig. 2. The genetic pedigree of family A.
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.2. Patient AA
The eldest sonhad intermittent vomiting fromage twoanddiar-
hoea from age four. In 1981 aged 12 years, he was admitted to
ospital with vomiting and suspected bulimia nervosa. However,
tenosis of the duodeno-jejunal junction leading to obstruction
as subsequently found at exploratory surgery, and a gastro-
ejunostomy performed. He continued to vomit and an antrectomy
as performed later that year. At 13 he was readmitted with poor
eight gain and a peptic ulcer was diagnosed. Symptoms persisted
nd at a third laparotomy, gastro-duodenal dilation was found,
o the gastro-jejunostomy was disconnected, the upper jejunum
esected and an end-to-end jejuno-jejunal anastomosis performed
ith a duodenoplasty. A further laparotomy for vomiting at age 14
fter treatment with cisapride and a period of parenteral nutrition,
esulted in a Roux-en-Y gastrojejunostomy. Intestinal neurohisto-
hemistry assessing adrenergic and cholinergic innervation was
ormal.
He was treated extensively at a tertiary children’s hospital in
ondon. On his ﬁnal hospital admission aged 15, he was 159 cm
all and weighed 28.5 kg (BMI 11.2 kg/m2). Lower limb weakness
nd foot drop with a broad-based gait was noted. Large joint
osition sense was poor, with marked sensory loss in feet and
nkles. By the age of 16, he was unable to stand without sup-
ort and had peripheral sensory loss in upper and lower limbs.
lectromyography showed a demyelinating polyneuropathy, with
hronic inﬂammation on a sural nerve biopsy. Brain CT scan, cere-
rospinal spinal ﬂuid and visual evoked responses were normal.
orrection of selenium and chromium deﬁciency had no effect.
hromosomal, hormonal and toxicology screens were normal or
egative. He had an episode of haemolytic anaemia (haemoglobin
alling to 3.7 g/dL). No single diagnosis could be reached. He was
ntermittently fed intravenously while his physical debility pro-
ressed, with treatment withdrawn ‘in the patient’s best interests,
ith no hope of a cure’. He died at home at the age of 17. The
eath certiﬁcate records bronchopneumonia, chronic malnourish-
ent, severe gastro-intestinal motility disorder and peripheral
europathy. A post-mortem showed that aspiration pneumonia
as due to mechanical intestinal obstruction from adhesions,
ith Clostridium difﬁcile colitis and emaciation as contributing
actors.
The differential diagnosis in the notes serially records Mun-
hausen’s syndrome, anorexia nervosa and severe peripheral
europathy of unknown cause. Comments are revealing: ‘physical
ymptoms are far from being purely psychosomatic, but consti-
ute signiﬁcant organic pathology, albeit with eternally puzzling
etiology’. Diagnostic and therapeutic manoeuvres had proved
singularly useless’. The ‘family psychopathology’ was said to be
untreatable’. The patient was said to be ‘depressed and have a love
f operations’, with an ‘obsessive interest inmedical conversation’.
.3. Patient BA
In 2004, AA’s sister presented at the age of 18 with neurological
ymptoms. She had a twomonth history of dropping objects, weak
rip strength and an inability to bend her foreﬁnger to her thumb.
he also had balance problems and had fallen; at presentation to
ccident and Emergency aged 17 with a sprained ankle, a bilateral
oot drop was noted. She subsequently described that her thighs
tarted burning after short walks, and she injured herself without
ealising it when shaving her legs. She was underweight, but not
nderdeveloped.
At the age of 18, she was investigated by her local neurol-
gy service. She had wasting of the thenar eminence and reduced
uscle tone in all four limbs. She was areﬂexic with down going
lantars, and had absent peripheral proprioception and vibrationLiver Disease 46 (2014) 1–8 3
sense and impaired sensation to pinprick or light touch. Nerve
conduction studies demonstrated a severe sensory and motor
peripheral neuropathy and a possible diagnosis of chronic inﬂam-
matory demyelinating polyneuropathy was suggested. She was
consequently treated with intravenous immunoglobulin, and also
received physiotherapy, ankle and wrist splints.
She was seen again later the same year, needing support to
walk. Nerve conduction studies were repeated and conﬁrmed sig-
niﬁcant deterioration. Shewas prescribed further immunoglobulin
and prednisolone. She deteriorated and was transferred to the
regional neurology service in Oxford, where it was noted that she
lacked the sensory features commonly associatedwithdemyelinat-
ing polyneuropathy. A trial of plasma exchange was unsuccessful.
Urinary thymidine (for thymidine phosphorylase deﬁciency)
was negative. This false negative result was likely due to bac-
terial degradation of urinary thymidine during transit and could
have been avoided either by adding preservative or by analysing
blood simultaneously. However, a muscle biopsy from the left del-
toid showed cytochrome oxidase negative ﬁbres consistent with
a mitochondrial myopathy. On DNA analysis, she was found to
carrymultiplemtDNAdeletions. At this stage shewas vomiting fre-
quently, with abdominal pain and constipation. She had lost close
to 40% of her body weight, and weighed 34kg (165 cm tall, BMI of
12.5 kg/m2).
The following year, it was decided to concentrate on
symptomatic management and nutrition. A percutaneous gastro-
jejunostomy (PEG-J) was inserted. Although she was said to eat
reasonably well, she had nocturnal vomiting, intermittent diar-
rhoea and was wheelchair bound. She died in hospital at the age of
19.
Final genetic analysis revealed that BA had MNGIE.
2.4. Patient CA
In January 2006, just months after the death of her sister, the
ﬁnal sibling CA presented aged 22 with weight loss, mild impair-
ment of balance, numbness andweakness of her toes. She weighed
37.6 kg. She had been thin since birth. At age 14 she had been
admitted to a children’s ward for ‘anorexia watch’. The stress of
the fatal illness of her siblings and ‘difﬁcult family dynamics’ were
considered to be contributory factors. Numbness in her feet ﬁrst
manifested as difﬁculty in driving, when she had difﬁculty inwork-
ing the pedals. Her thumbs had started to ‘lock’ and she was easily
tired. Gastrointestinal symptoms of bloating and abdominal pain
had led to a decreased appetite. She was easily satiated, frequently
nauseated and had increased bowel frequency. Domperidone pro-
vided some relief.
In view of her sister’s condition shewas admitted for an elective
muscle biopsy and clinical geneticist opinion. She had features of
external ophthalmoplegia, peripheral neuropathy and limb weak-
ness. Although her initial urinary thymidinewas borderline, repeat
urine and blood levels were elevated. Muscle biopsy showed fea-
tures consistent with a mitochondrial myopathy.
Multiple mitochondrial deletions were detected on DNA anal-
ysis. A diagnosis of MNGIE due to a defect in the thymidine
phosphorylase gene (homozygous for c.1431dupT, with a frame
shift leading to loss of authentic stop codon) was made and
functional thymidine phosphorylase activity was almost absent.
It is now accepted that the central pathogenic mechanism of
MNGIE is caused by defects in intergenomic communication, due
to mutations of the nuclear gene encoding thymidine phosphory-
lase controlling the replication and expression of themitochondrial
genome [20]. Thymidine phosphorylase reversibly phosphorylates
the nucleosides thymidine and deoxyuridine, levels of which are
usually undetectable in healthy individuals. CA’s urine deoxyuri-
dine and thymidine concentrations were 0.199 and 0.107mmol/l
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espectively. In addition, plasma concentrations of deoxyuridine
nd thymidine were found to be 20mol/l and 6mol/l.
Because thymidine phosphorylase is not expressed in skeletal
uscle, it was thought that enzyme replacement by bone marrow
ransplant might be beneﬁcial. Allogeneic stem cell transplanta-
ion had previously corrected biochemical derangements inMNGIE
21].
No bone marrow match, however, could readily be found for
A. Thymidine loadwas reduced by cutting dietary pyrimidine and
urine intake. Itwas suggested that high dose folate administration
ight increase the activity of thymidylate synthetase, an enzyme
hichmight contribute to raised deoxyruridine levels in urine [22].
Ubiquinone (CoEnzymeQ10) 300mgdailywas prescribed. Later
hat year, she had gained 0.8 kg in weight, but was walking with
stick and had worsening pes cavus. She was enrolled into a
ompassionate use study of carrier erythrocyte-entrapped thymi-
ine phosphorylase enzyme replacement therapy. This therapeutic
pproach was ﬁrst used in 2006 where a single administration of
rythrocyte encapsulated thymidine phosphorylase was given to a
eriously ill patient [23]. Although initial cycles evoked a dramatic
esponse in CA, later cycles provided only transient relief lasting 5
ays.
She stopped her low purine diet after 18 months despite initial
eight gain as the beneﬁt was not sustained. Metoclopramide was
ore successful than domperidone, amitriptyline, or bisacodyl at
elieving her nausea.
Attempts weremade at nasogastric feeding but were limited by
sensation of dysphagia. Barium swallow revealed no oesophageal
athologybut adelayedﬁlmshowedagrosslydilated stomachwith
arkedly delayed emptying. The globus type symptoms eventually
mprovedwith the addition of amitriptyline. Her nutritional status,
owever, became critical.
CA was admitted aged 23 (weight 32.7 kg) for intravenous
eeding via a peripherally inserted central catheter (PICC), after
reatment to prevent re-feeding syndrome following chronic
alnutrition, secondary to gastroparesis and gastrointestinal dys-
otility. It was considered that bowel symptoms were due to
trophy of smooth muscle and loss of mitochondrial activity in
utonomic nerves. Small bowel bacterial overgrowth was consid-
red a contributing factor, so ciproﬂoxacin was given on the ﬁrst
eekof everymonth.Omeprazolewasused for gastro-oesophageal
eﬂux related to gastroparesis, conﬁrmed by isotope gastric empty-
ng studies. Symptomatic control of abdominal pain was achieved
ith fentanyl patches and octreotide. Despite these interventions,
A died aged 24.
.5. Family B
A second family, a mother and son, who presented in adult-
ood with progressive ptosis, external ophthalmoplegia, fatigable
imb weakness and diabetes are described. Interestingly, gastroin-
estinal involvement was a dominant feature in the son but not
he mother. A diagnosis of mitochondrial disease due to complex
tDNA rearrangements was established.
.6. Patient AB
A 22 year old man presented in 1999 with a history of gas-
rointestinal disturbance, lower limb myopathy, ptosis, external
phthalmoplegia and heart block. Althoughmotor milestones dur-
ng childhood had been acquired normally, the patient had never
een as physically active as his two brothers, because he was eas-
ly fatigued. Apart from the mother, there was no family history
f illness, unexplained death, disease or consanguinity. He had
een seen by a paediatrician at ﬁve years of age, but no diagno-
is had been made. In early teenage years he developed a bilateralLiver Disease 46 (2014) 1–8
ptosis, more marked in the evenings. Gastrointestinal symptoms
became prominent, with intermittent diarrhoea and constipation,
aswell as a sensation of incomplete faecal evacuation.Hehad lower
abdominal, groin and anal pain, with bloating, although appetite
and body weight were normal. He also had infrequent episodes of
severe generalised colicky abdominal pain lasting several days at a
time and necessitating absence from school, although no investi-
gation had been undertaken. Heavy physical exertion was avoided
until the age of 17, when a job involving manual labour produced
exercise-relatedmuscle pain in the lower back and legs, relieved by
rest. From 18 years, the patient reported episodes of pre-syncope.
Heart block was discovered on a resting electrocardiogram, lead-
ing to cardiac pacemaker insertion at the age of 21. Diagnosis of
a probable mitochondrial disease in the mother led to referral of
the son to the mitochondrial genetics group for further investiga-
tion.
On examination he had bilateral ptosis, with external ophthal-
moplegia more marked in the horizontal plane. He had peripheral
retinal pigmentation, with preserved visual acuity. Upper limb
strengthwasnormal, butmuscle bulk in the lower limbswaspoorly
developed,withweakness and fatigability. Abdominal examination
was unremarkable.
Investigation of his gastrointestinal symptoms with esoph-
agogastroduodenoscopy (EGD), colonoscopy and small bowel
barium enema revealed only mild esophagitis and haemorrhoids.
A diagnosis of constipation-predominant intestinal dysmotility,
commonly found in mitochondrial disease, was made on clin-
ical grounds. Treatment with osmotic laxative, peppermint oil
and dietary advice to increase soluble ﬁbre led to symptomatic
improvement. His groin pain appeared to be neurogenic in origin,
although responded poorly to simple analgesics, amytriptyline, or
carbamazepine.
Muscle biopsy of the right quadriceps was performed. His-
tochemical staining was abnormal with scattered myoﬁbers
demonstrating excessive succinate dehydrogenase (SDH) activity
and several deﬁcient in cytochrome c oxidase (COX). There were
also structurally abnormal mitochondria on electron microscopy.
The ﬁndings were compatible with a mitochondrial myopathy.
Mitochondrial DNA analysis revealed a complex typemitochon-
drial DNA single rearrangement in muscle DNA. Southern blotting
of a SnaBI digest showed two bands of 11.7 and 28.3 kb, in addi-
tion to the normal 16kb band (Fig. 3). Regional probes showed
that these reﬂected anmtDNA deletion and a corresponding dupli-
cation (that is, a molecule corresponding to a deleted molecule
in series with a normal molecule) (Fig. 4). The junction frag-
ment for both deletion and duplication was hence the same [24].
Sequence analysis showed that the deletion constituted 4863bp
and the corresponding duplication 11,706bp (mapping from 9522
to 14,385 with 8bp almost exactly ﬂanking direct repeats). He
subsequently developed insulin dependent diabetes mellitus and
hypogonadism in his early thirties. Progressive sensorineural deaf-
ness, impairmentof visual acuity anddystonic tremorof bothhands
developed from his mid thirties. Gastrointestinal symptoms per-
sist, but have not deteriorated. His weight and appetite remain
stable.
2.7. Patient BB
As she had ptosis, the patient’s mother (then aged 46 years) was
investigated concurrently. From childhood she had been reluctant
to run or take vigorous exercise, with marked general fatigue by
early evening. This had allowed her to empathise with the physical
limitations in her son. Hypothyroidism was subsequently diag-
nosed, but thyroxine only improved, rather than eliminated her
fatigue. She had no gastrointestinal or cardiac symptoms. At the
age of 42 she had been referred for a neurological opinion with
T.P. Chapman et al. / Digestive and Liver Disease 46 (2014) 1–8 5
Fig. 3. Southern analysis. PvuII digest conﬁrmed the presence of an approximately 5kb (sized as 4.9 kb) rearrangement in muscle DNA from the son (AB) and mother (BB);
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other is single deletion; a low level of deletion dimer was detected in the mother
atigue and diplopia; she was treated for myasthenia gravis. When
here was no improvement in symptoms, an electromyogram was
erformed, revealing excessive polyphasic motor units, suggestive
f a myopathy rather than a neuromuscular transmission defect. A
uscle biopsy demonstrated features consistent with a mitochon-
rialmyopathy,which in turn had lead to appropriate investigation
f her son.
On examination she had mild bilateral ptosis, with external
phthalmoplegia in all planes. There was minor peripheral reti-
al pigmentation, but visual acuity was normal. Her upper limb
uscle bulk was normal, but with discernible weakness and fati-
ig. 4. Schematic diagram of mitochondrial DNA showing the location of SnaBI
nd PvuII restriction enzyme recognition sites, and illustrating rearranged mtDNA
olecules which commonly occur in patients with mtDNA rearrangements. The
ost commonly deleted region is indicated as a dashed line.proximately 10%. SnaBI digest showed that the major rearranged species in son and
level of duplication and very low level of deletion dimer was detected in the son.
gability. She had decreased muscle bulk in the lower limbs, with
demonstrable weakness and fatigability.
Mitochondrial DNA analysis of her muscle DNA revealed the
same mtDNA 4863bp deletion as her son, but no duplication
(Figs. 3 and 4). In addition to the 11,706bp deleted molecules, she
had a 23.4 kb band corresponding to deletion dimers (two deleted
molecules joined in series). As expected, the junction fragmentwas
identical for both rearranged molecules (Fig. 3).
A calcium channel antagonist (amlodipine), commenced by
a cardiologist for suspected exertional angina, led to marked
improvement in activity levels, fatigability and her range of eye
movements. Magnetic resonance spectroscopy during a standard
work-incremented exercise protocol (plantar ﬂexion) was per-
formed in order to assess the effect of amlodipine onmitochondrial
function and recovery from exercise. Following a two week trial
of amlodipine, there was signiﬁcant improvement in oxidative
ATP production in mitochondria measured by spectroscopy. The
calcium antagonist, nifedipine, is able to partially block ATP sen-
sitive potassium channels of the type found in skeletal muscle.
As these channels probably inﬂuence muscle fatigue, we reasoned
that amlodipine might improve fatigue by doing the same. Hence
we initiated a trial of amlodipine in the son but this provided no
symptomatic improvement.
The mother subsequently developed diabetes in her mid ﬁfties,
treated with oral hypoglycaemics. At 57 years old, she developed
paroxysmal atrial ﬁbrillation,which could not be prevented by beta
blockers or ﬂecainide. Most notably, she has never had the debil-
itating abdominal symptoms of pain, bloating and constipation
experienced by her son.
2.8. Family CWe ﬁnally describe a male patient, AC, with cognitive decline,
neuropathy andoptic atrophy,who later developedprominent gas-
trointestinal symptoms of dysphagia and vomiting. A diagnosis of
6 e and Liver Disease 46 (2014) 1–8
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utosomal dominant optic atrophy (DOA) due to a well established
athogenic mutation in the OPA1 gene was made. The Opa1 pro-
ein, encoded by OPA1, plays an important role in mitochondrial
ynamics, and thus gene mutations can lead to mitochondrial dis-
rders. He has no evidence of any mitochondrial DNA abnormality
owever. As patient AC has neurological features in addition to his
pticneuropathy, his condition is termed ‘DOAplus’ (for “Dominant
ptic Atropathy plus”).
AC ﬁrstmanifested signs of disease aged between two and three
ears. It was noted that he often fell over, overshot when reach-
ng for objects and failed to make eye contact with adults. He was
iagnosedwith optic atrophy, having had a right convergent squint
orrected at the age of 14 months old. There was an early history
f ‘failure to thrive’ and acid reﬂux.
He presented to local services in 2006, aged 9 with a two year
istory of motor problems, with weakness and unsteadiness. On
rain MRI, no destructive brain lesions were seen, with the only
bnormality small optic nerves and optic chiasm. Vision by this
tage was limited to perception of light only. No mutations in the
OLGgene,which encodes the catalytic subunit of themtDNApoly-
erase were found, nor was there evidence of Leber Hereditary
ptic Neuropathy. Urinary organic acids were normal.
By age 11, AC had leftmainstream schoolwith cognitive decline,
ysarthria and sensory ataxic neuropathy. He required callipers
o walk. Neuropathy was conﬁrmed on EMG with ‘sensory motor
xonal neuropathy affecting sensory ﬁbres more severely than
otor’. Amuscle biopsywas consistent with denervation and rein-
ervation but there was no evidence of mitochondrial disease.
By age12hewaswheelchair bound.Hehadmarkedneuropathic
ain and his co-ordination had deteriorated. He also had hearing
ifﬁculties, consistent with an auditory nerve neuropathy.
At age13, the genetics for his ‘DOAplus’ syndromeweredeﬁned.
ne copy: c.2707 2711deITTAGoriginated fromhispaternal grand-
ather. This is a well characterised mutation that leads to impaired
ision in 60% of individuals who carry it. The other copy in exon 6
f hisOPA1 genewas found in hismother: c.661G>A, a never before
escribed mutation predicted to be that of p.Glu221Lys. The optic
trophywas causedbyhypoplastic optic nerves, themechanism for
hichwas postulated to be due to increased ‘mitophagy’, a subtype
f autophagy, literally to ‘self-digest’. The ‘plus’ features included
ensory neuropathy and cognitive decline.
There was no family history of consanguinity. There was
owever a strong history of neurological and ophthalmological
mpairment. His paternal grandmother hadwhatwas thought to be
congenital’ right sided facial paralysis. Her maternal great grand-
other was blind from 15, and this grandmother’s brother and
isterhadsuffered fromblindnessandmobilityproblemsat ayoung
ge. A paternal uncle had epilepsy, a squint and minor learning
ifﬁculties.
At age 13, AC developed signiﬁcant gastrointestinal symptoms,
ith dysphagia and vomiting. A PEG was sited the same year,
ut he struggled with abdominal pain on feeding, relieved with
efecation. Aged 15 he was admitted with diarrhoea and had lost
0 kg in weight. Stool cultures were negative. EGD with duodenal
iopsies was normal. Ileocolonoscopy demonstrated oedematous
olonic mucosa with patchy erythema but no ulceration, and
ormal terminal ileum. Histopathology showed mild acute on
hronic colonic inﬂammation, with cryptolytic granulomas in the
ransverse colon. MRI enteroclysis suggested marked wall thick-
ning of the right colon consistent with an inﬁltrative process, but
as not typical of inﬂammatory bowel disease. The diarrhoea did
owever initially respond to a course of steroids.
AC was readmitted 6 days post discharge with severe abdomi-
al pain and further diarrhoea. Laparoscopy was performed but no
lear diagnosis reached. Following a haemoglobin drop of 5 g/dl, a
T scan to assess for haemorrhage revealed gas within the colonic Ta
b
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Table 2
Clinical clues and checklist of investigations for mitochondrial disease in a patient
with intractable symptoms of irritable bowel syndrome or suspected visceral
myopathy.
Careful re-clerking to include a systems enquiry, family history and full
neurological examination
Consider mitochondrial disease if gastrointestinal symptoms are associated
with additional organ involvement (for example):
• Nervous system: Developmental delay, seizures, ataxia, dystonia,
hemiparesis, visual loss, peripheral neuropathy
• Muscle: Weakness, exercise intolerance, ptosis, ophthalmoplegia
• Eye: Optic atrophy, retinal pigmentation, cataracts
• Auditory: Sensorineural hearing loss
• Endocrine: Diabetes mellitus, thyroid and pituitary dysfunction
• Cardiac: Cardiomyopathy, conduction disease
• Other: Fanconi syndrome, hepatopathy (abnormal liver function,
otherwise unexplained)
Investigations for mitochondrial disease (telephone the hospital Consultant
Clinical Biochemist or appropriate colleague to discuss)
• Plasma glucose (may detect diabetes mellitus, increasing likelihood of
mitochondrial disease)
• Electrocardiogram and echocardiogram (to explore potential cardiac
involvement)
• Fasting plasma lactate and pyruvate level
• Plasma and urinary thymidine and deoxyuridine
• Urinary organic acids
• Plasma acylcarnitines
• If abnormal neurology or evidence of muscle weakness, discuss with
Neurologists the role of
• Lumbar puncture with cerebrospinal ﬂuid analysis for lactate and protein
• ElectromyographyT.P. Chapman et al. / Digestiv
all, most marked in the right colon. A diagnosis of pneumatosis
oli wasmade and hewas treatedwith high ﬂow oxygen. It is plau-
ible that mitochondrial disease in the muscularis propria of the
ntestinemayhave renderedhimsusceptible to consequences from
n infective or ischaemic insult. He recovered and was discharged,
ut his prognosis from the underlying disease remains extremely
uarded.
Table 1 summarises the clinical and genetic features of the six
atients described in this paper.
. Discussion
Our case series highlights two important but poorly recognised
spects of mitochondrial disease: the clinical and the genetic. All
atients had clinical evidence of multisystem disease that is char-
cteristic of patients with more complex mitochondrial defects.
his is an important clinical signal, because it means that such
atients can present to any of many specialists, who will all (most
robably) be unfamiliar with mitochondrial disease. This contrasts
ith the common, sporadic chronic progressive external ophthal-
oplegia associated with single mtDNA deletions, where the main
eature is an isolated myopathy. Once again, this is an important
ducational point for clinicians, since most will assume that myo-
athic symptoms predominate in patients with a mitochondrial
isease and tend to ignore ‘non-speciﬁc features’ such as tired-
ess, easy fatigability, systemic symptoms, or diabetes. It is notable
or example that patient AB’s concerns were his gastrointestinal
ymptoms and neurogenic pain, which were potentially treatable
ymptoms, but which may not be given a high priority in a gen-
ral muscle clinic. Like a coin, a medical condition always has two
ides: what is familiar to one group of specialists may be obscure
o another.
Gastrointestinal symptoms are a major feature of MNGIE,
nd upper gut disorders including gastroparesis are common in
utosomal-inherited syndromes associated with multiple mtDNA
eletions such as Leigh syndrome [12,25]. In MNGIE, chronic
ntestinal pseudo obstruction (another term for severe intestinal
ysmotility) is a dominant symptom that can lead to intestinal
ailure requiring nutritional support [12]. It appears to be due to
arked atrophy of the external layer of the muscularis propria
n which there is prominent mitochondrial proliferation and loss
f cytochrome oxidase activity. Genetic analysis shows a selective
epletionofmtDNAconﬁned to the external layer of themuscularis
ropria of the small intestine [26,27]. Although this is a plausible
xplanation of the gut failure that can characterise MNGIE, recent
vidence suggests that loss of the intestinal interstitial cells of Cajal
ay also be important [28]. Cajal cells appear to have a high energy
equirement, since mitochondria comprise 5–10% of their cyto-
lasmic volume, so their function is likely to be badly affected
y mitochondrial disease. This is consistent with morphometric
bservations dating back decades that have found abnormal inter-
titial cells of Cajal in Hirschsprung disease, non-speciﬁc chronic
ntestinal pseudo-obstruction and idiopathic intractable constipa-
ion [29]. Interestingly, mtDNA has recently been implicated in
ome patients with irritable bowel syndrome, which suggests that
here may indeed be a spectrum of mtDNA disorders reﬂected in a
pectrum of intestinal motility disorders [30]. If this is conﬁrmed,
t would shed substantial light on the pathophysiological darkness
f intestinal dysmotility.
An intriguing aspect of Family B is why gastrointestinal symp-
oms were so prominent in the son and almost absent in the
other. The key genotypic difference between mother and son
as the presence of the 11,706bp duplication (mapping from 9522
o 14,385) in the latter. We suggest that the mother may have
arried mtDNA duplications in her oocytes, but lost them progres-
ively from her muscle, as in a previous report [31]. It is tempting• Nerve conduction studies
• Magnetic resonance imaging of brain
• Muscle biopsy for histological and histochemical analysis
to speculate that the duplication might account for the visceral,
intestinal symptoms in the son’s phenotype, while the 4863bp
deletion common to bothmother and son accounted for the effects
on the peripheral muscles. It is only conjecture, but a possibility
worth pursuing, since it is a common clinical observation that some
patients with amitochondrial disease have severe intestinal symp-
toms and others are relatively spared. Our ﬁndings illustrate the
need for precise analysis of individual mtDNA, since duplications
and higher order mtDNA rearrangements are often overlooked on
routine testing.
Although mitochondrial disease cannot currently be cured, in
recent years four exciting potential therapies have emerged. Firstly,
the use of allogeneic hematopoietic stem cell tranplantation to
restore thymidinephosphorylaseactivity inMNGIE showspromise.
It has been effective in 5 of 11 patients treated to date, with the ﬁrst
transplanted patient showing markedly improved gastrointestinal
function [32]. A prospective clinical trial is planned. Secondly, there
is interest in the beneﬁts of promoting new mitochondrial forma-
tion (biogenesis) and function. Particular attention has focused on
the transcriptional coactivator, peroxisome proliferator-activated
receptor (PPAR) y coactivator-1 protein (PGC-1) which is a
strong promoter ofmitochondrial biogenesis. Recently bezaﬁbrate,
a drug treatment for hyperlipidaemia, has been shown to stimu-
late PGC-1 activity and improve mitochondrial respiratory chain
function in cell lines of patients with mtDNA disease [33]. Thirdly,
the use of gene therapy to prevent mtDNA transmission in affected
families appears feasible, although there are clear ethical consid-
erations with donor mtDNA from unaffected individuals required
[34]. Finally, the efﬁcacy of CoEnzymeQ10 (ubiquinone) in patients
with CoEnzyme Q10 deﬁciency is noteworthy. This is an exam-
ple of a mitochondrial disorder resulting from the deﬁciency of
a key metabolite that can be treated with supplementation [35].
Unfortunately the beneﬁts of CoEnzymeQ10donot extend to other
mitochondrial disorderswhich have quite separate pathophysiolo-
gies, underlining the challenges of developing treatments for this
heterogeneous group of diseases [35].
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Mitochondrial disease should be part of the differential diag-
osis for anorexia nervosa and also for medically unexplained
astrointestinal symptoms. We conclude by proposing a checklist
f investigations that may be helpful in establishing a diagnosis
f mitochondrial disease (Table 2). The checklist cannot be com-
rehensive, but should increase awareness that apparently rare
itochondrial disorders can account for common symptoms. The
ey component is the alert physician, whether in primary or sec-
ndary care: when the clinical picture cannot readily be explained
nd does not quite ﬁt (such as unaccountable weight loss in some-
ne with irritable bowel syndrome), mitochondrial disease should
e considered. The checklist includes rudimentary questions per-
aining to family history and a full neurological examination that
ight provide the initial clues to an organic cause. At present a cor-
ect diagnosiswill guide supportivemanagement andallowgenetic
ounselling, but as outlined above there is also reason to hope that
ffective treatments may soon be available. The true prevalence
f mitochondrial disease may well be masked by failing to con-
ider the diagnosis, which in turn limits the research that could
otentially ameliorate outcomes for these patients.
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